Effect of Disease Activity at Three and Six Months After Diagnosis on Long‐Term Outcomes in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Abstract

The results of this study suggest that disease status at 3 and 6 months following the diagnosis of AAV may be predictive of the long-term risk of mortality and ESRF, and therefore these may be valid end points for induction trials in AAV. The current findings need to be validated in a larger data set.